Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Jie Shen
Brigham and Women's Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
iNeuro Therapeutics
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
The research is related to the function of Presenilin in Alzheimer’s disease. iNeuro is developing an assay that screens for compounds that increase Presenilin/gamma-secretase activity. If Presenilin is determined to be key to mechanisms related to AD, this could increase demand for the Presenilin screening assay.
APP/APLP1/APLP2 in the brain
Alzheimer's disease (AD) is the most common neurodegenerative disorder, and mutations in the amyloid precursor protein (APP) and the presenilins are linked to inherited forms of the disease. Our previous genetic studies elucidated the roles of presenilins in the developing and adult brain; however, the normal physiological role of APP remained elusive due to genetic redundancies and the lack of appropriate conditional mutant mice. We propose to uncover normal physiological roles of APP in mature neurons and synapses through the generation of cell type-specific conditional null mutant mice lacking all three members of the APP family.
Filed on June 12, 2018.
Tell us what you know about Jie Shen's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Jie Shen filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Jie Shen | Brigham and Women's Hospital | Conflict of Interest | iNeuro Therapeutics | $40,000 - $59,999 |
| Jie Shen | Brigham and Women's Hospital | Conflict of Interest | iNeuro Therapeutics, Inc. | $40,000 - $59,999 |
| Jie Shen | Brigham and Women's Hospital | Conflict of Interest | iNeuro Therapeutics | $40,000 - $59,999 |
| Jie Shen | Brigham and Women's Hospital | Conflict of Interest | iNeuro Therapeutics | $40,000 - $59,999 |
| Jie Shen | Brigham and Women's Hospital | Conflict of Interest | iNeuro Therapeutics | Value cannot be readily determined |
| Jie Shen | Brigham and Women's Hospital | Conflict of Interest | iNeuro Therapeutics | Value cannot be readily determined |
| Jie Shen | Brigham and Women's Hospital | Conflict of Interest | iNeuro Therapeutics, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.